Hyperledger Project Explores Fighting Counterfeit Drugs with Blockchain
Hyperledger project member Accenture has proposed using blockchain tech to fight the spread of counterfeit drugs.
At a working group meeting of the Hyperledger blockchain project today, a representative for global professional services company Accenture pitched the early phases of a project designed to fight the spread of counterfeit drugs using blockchain technology.
The details came during a meeting of the initiative's working group focused on project requirements.
Accenture's connected devices software lead Primrose Mbanefo, who works with its Internet of Things business development team and helps produce some of the company’s proofs-of-concept, described how more efficient tracking of medicines using immutable data could improve accountability in the pharmaceutical industry.
A key point up for debate at the meeting was the question of defining what exactly constitutes counterfeit activity in the pharmaceutical industry. According to Mbanefo, counterfeiters include both “rogue” manufacturers and established companies around the world that are failing to include the right amounts of active ingredients in medicines – or none at all.
"That would be cleared up if we had a supply chain we could actually trust," she said.
The idea of using distributed time-stamping to differentiate counterfeit drugs is a compelling one, given the success of the trade.
In the United Kingdom, where Mbanefo is based, a counterfeit medicines bust last June resulted in the seizure of 6.2 million doses or medical devices, worth £15.8m. According to the BBC report, a total of £51.6m of counterfeit medical goods around the world were confiscated during that one operation.
The control of the counterfeit drugs problem is just one supply chain-focused use case being looked at by members of the Hyperledger project.
of blockchain in supply chains include tracking the manufacture and assembly of computer components, assessing the quality of milk products shipped and sold and confirming the veracity of food labels.
Photo of pills via Shutterstock
The leader in news and information on cryptocurrency, digital assets and the future of money, CoinDesk is a media outlet that strives for the highest journalistic standards and abides by a strict set of editorial policies. CoinDesk is an independent operating subsidiary of Digital Currency Group, which invests in cryptocurrencies and blockchain startups. As part of their compensation, certain CoinDesk employees, including editorial employees, may receive exposure to DCG equity in the form of stock appreciation rights, which vest over a multi-year period. CoinDesk journalists are not allowed to purchase stock outright in DCG.
Learn more about Consensus 2024, CoinDesk’s longest-running and most influential event that brings together all sides of crypto, blockchain and Web3. Head to consensus.coindesk.com to register and buy your pass now.